Hepatitis B Virus Market
Global Hepatitis B Virus Market Size, Share & Trends Analysis Report By Type (Acute and Chronic), By Distribution Channel (Online Pharmacies and Offline Pharmacies), and By Treatment (Anti-Viral Drugs, Vaccine, and Immune Modulator Drugs) Forecast Period (2022-2028)
The global hepatitis B virus market is anticipated to grow at a significant CAGR of 4.1% during the forecast period. Hepatitis B is an infection caused by the hepatitis B virus, which targets and damages the liver. According to the World Health Organisation (WHO) in 2019, hepatitis B affected 296 million individuals globally and chronic hepatitis B infected 1.5 million persons for the first time. Additionally, in 2021, WHO estimated that around 12% to 25% of people with chronic hepatitis B infection required treatment. Hepatitis B is known as a silent epidemic since most persons who are newly infected or have been infected for a long time do not show any symptoms. As a result, individuals may inadvertently spread the virus to others, contributing to hepatitis B's quite spread. Increased knowledge of the disease and treatment along with a growing number of cases, is expected to be the key factors driving this market.
Impact of COVID-19 Pandemic on Global Hepatitis B Virus Market
The COVID-19 pandemic had impacted the global hepatitis market significantly owning to the lockdown in most of the nations to control the spread of the virus. The impact of the COVID-19 pandemic on healthcare resources had a negative influence on chronic disease patient treatment and results. As a result, the treatment, diagnosis, and follow-up of individuals with liver disease and hepatitis have decreased, resulting in negative effects for the healthcare industry as a whole. Additionally, drug clinical trials have been slowed as most corporations have postponed the initiation of most new studies in multiple nations. Furthermore, the COVID-19 pandemic had resulted in a drop in outpatient services for chronic hepatitis patients, which had a significant influence on total market growth.
Segmental Outlook
The global hepatitis B virus market is segmented based on type, distribution channel, and treatment. Based on the type, the market is sub-segmented into acute and chronic. Based on the distribution channel, the market is sub-segmented into online pharmacies and offline pharmacies. Based on treatment, the market is sub-segmented into anti-viral drugs, vaccines, and immune modulator drugs. In the distribution channel, the offline pharmacies dominated the global market with a significant share, and it is likely to continue to do so throughout the projection period owing to the high amount of products supplied in hospitals.
Global Hepatitis B Virus Market Share by Treatment, 2021 (%)
The Vaccine Segment Holds The Major Share in the Global Hepatitis B Virus Market
The vaccine segment holds the major market share and is anticipated to grow significantly during the forecast period in the global hepatitis B virus market in the treatment segment owing to its protection against various causative agents. Various manufacturing companies such as GlaxoSmithKline and Sanofi are also providing combination vaccination that supports in driving segmental market growth by lowering the cost of packaging for separate vaccines. These vaccines are normally provided to newborn infants or immune-compromised patients to boost their resistance to a variety of infections.
Regional Outlooks
The global Hepatitis B virus market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Hepatitis B Virus Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Hepatitis B Virus Market
Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the hepatitis B virus market. Emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall hepatitis market. Due to the rising prevalence of hepatitis in impoverished areas of the region, Asia-Pacific is predicted to expand at the fastest rate during the forecast period. The region's growth will be aided by rising disposable income and rising GDPs in several countries.
Market Players Outlook
The major companies serving the global hepatitis B virus market include Merck & Co. Inc., GlaxoSmithKline plc., Sanofi, Dynavax Technologies, LG Chem, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2021, GlaxoSmithKline (GSK) had launched a new clinical trial, which is known as B-Together, in order to investigate how two study drugs might work together for the purpose of providing treatment to chronic hepatitis B (CHB).
In March 2021, one of the Turkish medicine companies named Turk Ilac had agreed with a Korean firm LG Chem for the purpose of producing Hepatitis B vaccines.
In February 2018, Janssen Pharmaceutical, a company of Johnson & Johnson did collaborate with Arrowhead Pharmaceuticals, Inc. for an exclusive, global license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous RNAi therapy candidate being studied for the treatment of persistent HBV infection.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global hepatitis B virus market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Hepatitis B Virus Market
- Recovery Scenario of Global Hepatitis B Virus Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Merck & Co., Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. GlaxoSmithKline plc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Sanofi
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Dynavax Technologies
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. LG Chem
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Hepatitis B Virus Market by Type
4.1.1. Acute
4.1.2. Chronic
4.2. Global Hepatitis B Virus Market by Distribution Channel
4.2.1. Online Pharmacies
4.2.2. Offline Pharmacies
4.3. Global Hepatitis B Virus Market by Treatment
4.3.1. Anti-Viral Drugs
4.3.2. Vaccine
4.3.3. Immune Modulator Drugs
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Arbutus Biopharma
6.2. Arrowhead Pharmaceuticals, Inc.
6.3. Bristol-Myers Squibb Company
6.4. F. Hoffmann-La Roche Ltd.
6.5. Gilead Sciences, Inc.
6.6. Janssen Global Services, LLC,
6.7. Johnson & Johnson
6.8. Novartis AG
GLOBAL HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ACUTE HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CHRONIC HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
5. GLOBAL ONLINE PHARMACIES HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OFFLINE PHARMACIES HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
8. GLOBAL ANTI-VIRAL DRUGS FOR HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL VACCINE FOR HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL IMMUNE MODULATOR DRUGS FOR HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
15. NORTH AMERICAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
16. EUROPEAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. EUROPEAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
19. EUROPEAN HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
24. REST OF THE WORLD HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. REST OF THE WORLD HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
27. REST OF THE WORLD HEPATITIS B VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL HEPATITIS B VIRUS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL HEPATITIS B VIRUS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL HEPATITIS B VIRUS MARKET, 2022-2028 (%)
4. GLOBAL HEPATITIS B VIRUS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ACUTE HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CHRONIC HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL HEPATITIS B VIRUS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
8. GLOBAL ONLINE PHARMACIES HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OFFLINE PHARMACIES HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL HEPATITIS B VIRUS MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
11. GLOBAL ANTI-VIRAL DRUGS FOR HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL VACCINE FOR HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL IMMUNE MODULATOR DRUGS FOR HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL HEPATITIS B VIRUS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
17. UK HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD HEPATITIS B VIRUS MARKET SIZE, 2021-2028 ($ MILLION)
